Background illustration for clinical trials search

Paid Clinical Trials Plainfield

Discover 2,380 paid clinical trials in Plainfield, Illinois. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Location: New Lenox IL, Glenview IL, Merrillville IN, Carmel IN,
Sponsor: Dendreon

Sex: Male

Age: 18+

Code: NCT06134232

Phase 2, Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for
Metastatic Solid Tumor, Advanced Solid Tumor,
Location: New Lenox IL, Milwaukee WI, Columbus OH, Nashville TN,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06561685

Phase 1, Recruiting

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

for
Aortic Stenosis, Severe
Location: New Lenox IL, Elk Grove Village IL, Evanston IL,
Sponsor: Edwards Lifesciences

Sex: All

Age: 0+

Code: NCT05172960

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

for
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma,
Location: New Lenox IL, Orland Park IL, Chicago IL, Munster IN,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05890352

Phase 2, Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

for
Recurrent B-Cell Non-Hodgkin Lymphoma,
Location: New Lenox IL, Orland Park IL, Chicago IL, New York NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05272384

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for
Myelodysplastic Syndrome
Location: New Lenox IL, Warrenville IL, Orland Park IL, Geneva IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase 2, Recruiting

PRE-ISPY Phase I/II Oncology Platform Program

for
HER2-positive Breast Cancer, Metastatic Cancer,
Location: New Lenox IL, Orland Park IL, Chicago IL,
Sponsor: QuantumLeap Healthcare Collaborative

Sex: All

Age: 18+

Code: NCT05868226

Phase 1, Phase 2, Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

for
Advanced Lung Neuroendocrine Tumor,
Location: New Lenox IL, Orland Park IL, Chicago IL, St Louis MO,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04665739

Phase 2, Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

for
Metastatic Digestive System Neuroendocrine Tumor G1,
Location: New Lenox IL, Warrenville IL, Orland Park IL, Geneva IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05773274

Phase 2, Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

for
Advanced Extrapulmonary Neuroendocrine Carcinoma,
Location: New Lenox IL, Warrenville IL, Orland Park IL, Geneva IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05058651

Phase 2, Phase 3, Recruiting

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

for
Locally Recurrent Skin Squamous Cell Carcinoma,
Location: New Lenox IL, Orland Park IL, Harvey IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07042295

Phase 2, Recruiting

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

for
Accelerated Phase Myeloproliferative Neoplasm,
Location: New Lenox IL, Orland Park IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06661915

Phase 2, Recruiting

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for
B Acute Lymphoblastic Leukemia
Location: New Lenox IL, Orland Park IL, Maywood IL, Chicago IL,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18 - 39

Code: NCT03150693

Phase 3, Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative,
Location: New Lenox IL, Orland Park IL, Maywood IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03739814

Phase 2, Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for
Acute Myeloid Leukemia
Location: New Lenox IL, Warrenville IL, Orland Park IL, Geneva IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06672146

Phase 2, Recruiting

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

for
Advanced Hepatocellular Carcinoma,
Location: New Lenox IL, Orland Park IL, Chicago IL,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT07166406

Phase 3, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for
Core Binding Factor Acute Myeloid Leukemia
Location: New Lenox IL, Orland Park IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase 2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for
Advanced Malignant Solid Neoplasm,
Location: New Lenox IL, Warrenville IL, Downers Grove IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase 2, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for
Acute Myeloid Leukemia,
Location: New Lenox IL, Orland Park IL, Maywood IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase 2, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for
Acute Myeloid Leukemia
Location: New Lenox IL, Orland Park IL, Maywood IL, Chicago IL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase 2, Recruiting